White Timothy Ogden 4

What Happened

• Timothy Ogden, President of Alamar Biosciences (ALMR), received equity awards and underwent share reclassifications. He was granted 163,358 RSUs (reported as a derivative grant on 2026-04-16) and 37,220 RSUs (granted 2026-04-20) — a total of 200,578 RSUs — each reported at $0.00 (no cash paid). Separately, entries show a reclassification/conversion of 454,583 Class B shares into Common Stock and a series of matching “other acquisition or disposition (J)” entries (various small lots) reported at $0.00, which reflect non‑cash reclassification/conversion activity rather than open‑market trades.

Key Details

• Transaction dates and prices: grants on 2026-04-16 (163,358 RSUs) and 2026-04-20 (37,220 RSUs); multiple reclassification/conversion entries on 2026-04-20 and 2026-04-16 — all at $0.00 (no cash exchanged).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Notable footnotes from the filing:
  • F1: Each Class B share was reclassified into one share of Common Stock immediately prior to the IPO.
  • F2: RSU grants vest monthly from the grant date, subject to continued service.
  • F3–F9/F4: describe vesting schedules for various option grants (some monthly, some 25% cliff + monthly thereafter; one footnote indicates fully vested).
• Filing timeliness: Form filed 2026-04-20 covering transactions on 2026-04-16 and 2026-04-20; this filing date appears timely (no late‑filing flag shown).

Context

• These were awards and reclassifications — not open‑market purchases or cash sales — so they reflect company equity compensation and structural conversion (Class B → Common) rather than a CEO buying or selling stock in the market. RSUs vest over time (see F2), so the reported grants do not immediately represent freely tradable shares unless specified otherwise.